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Summary 
Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive disease with a poor 
prognosis in which nuclear factor kappa B (NF-κB) is thought to play a role. This study 
explored the effects of histone deacetylase inhibitors (HDACIs) MS-275, 
suberoylanilide hydroxamic acid (SAHA), and LBH589 on both human T-cell 
lymphotropic virus type I (HTLV-1)-infected T cells (MT-1, -2, -4, and HUT102) and 
freshly isolated ATL cells harvested from patients. HDACIs effectively inhibited the 
proliferation of these cells. For example, MS-275, SAHA, and LBH589 effectively 
inhibited the proliferation of MT-1 cells with ED50s of 6 μM, 2.5 μM, and 100 nM, 
respectively as measured by 3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide assay on day 2 of culture. In addition, HDACIs induced cell cycle arrest at the 
G2/M phase and apoptosis of HTLV-1-infected T-cells in conjunction with regulation of 
apoptosis-related proteins. Electrophoretic mobility shift assay showed that exposure of 
HTLV-1-infected T-cells to HDACIs for 48 h inhibited formation of the NF-κB/DNA 
binding complex. Moreover, we found that HDACIs accumulated NF-κB and inhibitory 
subunit of NF-κB in the cytoplasm in conjunction with the down-regulation of NF-κB
in the nucleus, suggesting that HDACIs blocked nuclear translocation of NF-κB. Based 
on these findings, we believe HDACIs can be useful for treating patients with ATL or 
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other types of cancer in which NF-κB plays a role. 
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Introduction 
       Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4+ T 
lymphocytes for which human T-cell lymphotropic virus type I (HTLV-I) has been 
recognized as the etiologic agent [1,2]. Despite the development of intensive 
combination chemotherapy regimens supported by granulocyte colony-stimulating 
factor, the median survival time of individuals with ATL is less than 13 months [3,4]. 
Nuclear factor κB (NF-κB) regulates the expression of anti-apoptotic proteins 
including Bcl-2 family members as well as X-linked inhibitor of apoptosis protein 
(XIAP). ATL cells aberrantly express these anti-apoptotic proteins via NF-κB signaling, 
which is associated with the resistance of these cells to apoptosis mediated by 
anti-cancer agents [5-7].
Histone deacetylase inhibitors (HDACIs) have emerged as a potentially 
promising new class of anticancer drugs [8]. These include the hydroxamic acid derived 
suberoylanilide hydroxamic acid (SAHA), LBH 589, and tricostatin A (TSA), cyclic 
depsipeptide FR901228, and benzamide MS-275 [8]. HDACIs induce the growth arrest 
and apoptosis of cancer cells by manipulating the transcription of genes involved in 
regulation of the cell cycle, apoptosis, as well as, differentiation [8]. For example, we 
previously showed that SAHA induces growth arrest and apoptosis of human mantle 
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cell lymphoma cells in association with induction of the histone acetylation of P21waf1
promoter region, resulting in the up-regulation of P21waf1 protein [9]. 
Recently, a new mode of action for HDACIs has been identified in which TSA 
and FR901228 inhibit NF-κB/DNA binding activity in HTLV-1-infected T-cells and 
murine epidermal skin JB6, respectively [5,10]. However, the precise mechanism by 
which HDACIs inhibit NF-κB remains to be fully elucidated.  
This study explored the effects of the HDACIs MS-275, SAHA, and LBH589 
on NF-κB signaling in HTLV-1-infected T-cells. Exposure of these cells to HDACIs 
increased their levels of inhibitory subunit of NF-κB (IκB) and NF-κB in the cytoplasm 
in conjunction with the down-regulation of NF-κB in the nucleus, resulting in the 
inhibition of NF-κB signaling and induction of apoptosis of these cells.  
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Materials and Methods.
Cells. HTLV-1-infected T-cell lines MT-1, MT-2, and MT-4 were the kind gifts of I. 
Miyoshi (Kochi Medical School, Kochi, Japan). MT-1 is a leukemia T-cell line 
established from the leukemia cells of a ATL patient with the disease [1]. MT-2 and -4 
are HTLV-1-transformed cell lines established using an in vitro co-culture protocol [11]. 
The HUT102 cells were generously provided by Y. Maeda (Kinki University School of 
Medicine, Osaka, Japan). Cells were suspended in standard RPMI 1640 medium (Sigma, 
St. Louis, Missouri) supplemented with 10% heat inactivated fetal bovine serum. ATL 
cells were freshly isolated from patients with acute-type ATL once informed consent 
was obtained. CD4+ T lymphocytes were isolated from healthy volunteers by magnetic 
cell sorting utilizing CD4 MicroBeads as the manufacturer recommended (Miltenyi 
Biotec GmbH, Germany). 
Reagents. MS-275 and LBH589 were provided by Schering AG (Berlin, Germany) and 
Novartis (Basel, Switzerland), respectively. SAHA was kindly provided by Dr. V.M. 
Richon (Merk, New Jersey, USA). All reagents were dissolved in 100 % dimethyl 
sulfoxide (DMSO; Burdick & Jackson, Muskegon, MI) to a stock concentration of 10-2
M and stored at -80°C.  
MTT Assays. HTLV-1-infected cells (5x105/ml) were cultured with various 
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concentrations of HDACIs for 2 days in 96-well plates (Flow Laboratories, Irvine, CA). 
After culture, cell number and viability were evaluated by measuring the 
mitochondrial-dependent conversion of the 3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl 
tetrazolium salt (MTT) (Sigma) to a colored formazan product. 
Cell Cycle analysis by Flow Cytometry. Cell cycle analysis was performed as 
previously described [12]. 
Apoptosis Assays. The ability of HDACIs to induce apoptosis of HTLV-1-infected 
T-cells was measured using an annexin V-FITC apoptosis detection kit according to the 
manufacturer’s instructions (Pharmingen, Inc., San Diego, CA). 
Electrophoretic Mobility Shift Assay (EMSA). Electrophoretic mobility shift assay 
(EMSA) was done as previously described [13]. Briefly, 4 μg of nuclear extract was 
incubated with 16 fmol 32P-end labeled NF-κB binding probe. The DNA-protein 
complex was separated from the free oligonucleotide on a 5% polyacrylamide gel. Gels 
were dried and exposed to Kodak XAR film (Eastman Kodak, New Haven, CT). 
Western Blot Analysis. Western blot analysis was performed as described previously 
[12].Protein concentrations were quantitated using a Bio-Rad assay (Bio-Rad 
Laboratories, Hercules, CA). Proteins were resolved on a 10% SDS polyacrylamide gel, 
transferred to an immobilon polyvinylidene difluoride membrane (Amersham Corp., 
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Arlington Heights, IL), and probed sequentially with antibodies. Anti-IκBα (Imgenex, 
San Diego, CA), anti-p65 subunit of NF-κB (Santa Cruz Biotechnology, Santa Cruz, 
CA), anti-XIAP (Cell Signaling Technology Inc., Beverly, MA), anti-Bcl-2 (Santa Cruz), 
anti-Bcl-xL (Santa Cruz), and anti-α-tubulin (Santa Cruz Biotechnology) antibodies 
were used.
Statistical analysis. Statistical analyses were carried out by paired t-test using SPSS 
software (SPSS Japan, Tokyo, Japan). The results were considered to be significant 
when the P-value was < 0.05, and when the P-value was < 0.01, highly significant.
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Results. 
Effect of HDACIs on HTLV-1-infected T-cells.  
To examine the effects of HDACIs on the growth of HTLV-1-infected T-cells, we 
cultured these cells in the presence of various concentrations of either MS-275 (0.1-6 
μM), SAHA (0.1-5 μM) or LBH589 (10-1000 nM). Cell viability was assessed using 
the MTT assay on day 2 of culture, and the results were graphed and the effective dose 
that inhibited 50 % growth (ED50) of these cells was calculated (Fig 1) (Table 1). 
MS-275 inhibited the growth of MT-1, -2, and -4 cells with an ED50 of approximately 6 
μM (Fig 1A, Table 1). MS-275 (4 μM, 48 h) inhibited the growth of HUT102 cells by 
30 %, although ED50 was not reached (Fig 1A, Table 1). LBH589 potently inhibited the 
growth of MT-1 and -4 cells (ED50 of 100 and 58 nM, respectively) (Fig 1B, Table 1). 
SAHA also effectively inhibited growth of the HTLV-1-infected T-cells (ED50 ranging 
from 2.7 to 8.8 μM) (Fig 1C, Table 1). 
Effect of MS-275 on the cell cycle distribution of HTLV-1-infected T-cells. 
To investigate the mechanisms by which MS-275 inhibited the growth of 
HTLV-1-infected T-cells, we analyzed the cell cycle distribution after exposure of these 
cells to MS-275 (Fig 2). MS-275 (3 or 6 μM, 48h) prominently induced the 
accumulation of HTLV-1-infected T-cells at the pre-G1 phase of the cell cycle, a feature 
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characteristic of apoptosis, with a concomitant decrease in the proportion of cells in the 
S phase (Fig 2). In addition, MS-275 increased the percent of cells in the G2/M phase 
(Fig 2). For example, exposure of MT-1 or -2 cells to MS-275 (3 μM, 48 h) caused the 
accumulation of the mean 19 ± 7 and 32 ± 7 % cells in G2/M phase of the cell cycle 
versus a mean 8 ± 3 and 19 ± 6 % in the diluent treated control cells, respectively (Fig 
2).    
MS-275 induced apoptosis of HTLV-1-infected T-cells. 
To confirm further the ability of MS-275 to induce apoptosis of HTLV-1-infected T-cells, 
annexin V staining was utilized (Fig 3). Annexin V binds to cells that express 
phosphatidylserine on the outer layer of the cell membrane, a characteristic of cells 
entering apoptosis [14]. Exposure of HTLV-1-infected T-cells to MS-275 (6 μM, 48h) 
profoundly increased the population of cells that became positive for Annexin V 
(32-67 %) (Fig 3). 
Effect of HDACIs on cell cycle and apoptosis-related proteins in HTLV-1-infected 
T-cells. We next examined whether HDACIs modulated the cell cycle and the level of 
apoptosis-related proteins in HTLV-1-infected T-cells by Western blot analysis (Fig 4). 
HTLV-1-infected T-cells aberrantly expressed XIAP, which was consistent with 
previous studies [6], and exposure of these cells to MS-275 (3 or 6 μM, 48 h) 
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prominently decreased levels of this anti-apoptotic protein (Fig 4A). Expression of 
p21waf1 was not detectable in MT-1 and HUT102 cells (Fig 4A); exposure of these cells 
to MS-275 (3 or 6 μM, 48 h) dramatically induced p21waf1 levels (Fig 4A). MT-2 and -4 
cells slightly expressed p21waf1 protein, which dramatically increased after exposure to 
MS-275 (3 or 6 μM, 48 h) (Fig 4A). Similarly, LBH589 or SAHA decreased levels of 
XIAP in conjunction with the up-regulation of p21waf1 in MT-1 and -4 cells (Fig 4B). 
XIAP is a key member of the apoptosis protein family inhibitors, which block apoptosis 
by blocking the activity of caspase-3, -7, and -9 [14]. We, therefore, examined whether 
down-regulation of XIAP correlate with activation of caspases. As expected, cleavage of 
caspase 3, indicating activation of this cysteine protease, was apparently induced after 
exposure to MS-275 (3 or 6 μM, 48 h) (Fig 4A). Modulation of the levels of Bcl-2 
family members in HTLV-1-infected T-cells after exposure to MS-275 was cell-type 
specific (Fig 4A). MS-275 (3 or 6 μM, 48 h) increased levels of Bcl-2 and Bcl-xL in 
MT-1 and -2 cells, while these proteins were down-regulated in HUT102 cells (Fig 4A). 
Exposure of MT-4 cells to MS-275 (3 or 6 μM, 48 h) decreased levels of Bcl-xL, while 
levels of Bcl-2 were not modulated in these cells (Fig 4A).  
Effect of HDACIs on NF-κB activity in HTLV-1-infected T-cells. 
XIAP is one of the NF-κB target genes [14]. Thus, we examined whether HDACIs 
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affected NF-κB activity in HTLV-1-infected T-cells by utilizing EMSA (Fig 5). 
Exposure of MT-1 cells to either MS-275 (6 μM, 48 h), LBH589 (100 nM, 48h), or 
SAHA (5 μM, 48h) almost completely disrupted formation of the NF-κB/DNA binding 
complex (Fig 5). Similarly, MS-275 (6 μM, 48 h) completely inhibited NF-κB/DNA 
binding formation in MT-4 cells (Fig 5). MS-275 (6 μM, 48 h) also interfered with 
formation of the NF-κB/DNA binding complex in HUT102 and MT-2 cells, although 
the effect was less dramatic compared to that occurred with the other cell lines (Fig 5). 
The specificity of the NF-κB band was confirmed by competing with 100-times molar 
excess of unlabeled wild type oligonucleotides, but not mutated oligonucleotides (Fig. 
5). 
Activation of NF-κB involves two important steps: First, the phosphorylation 
and subsequent degradation of IκBα caused by IκB kinase, resulting in the release of 
NF-κB; and second, the nuclear translocation of the activated NF-κB. To elucidate the 
effect of MS-275 on these steps, we measured the levels of NF-κB proteins in the 
cytoplasm and nucleus of the HTLV-1-infected T-cells after their exposure to MS-275 
(Fig 6). IκBα and NF-κB accumulated in the cytoplasm (Fig 6A). Concomitantly, levels 
of NF-κB prominently decreased in the nucleus (Fig 6B), suggesting that MS-275 
blocked translocation of NF-κB from the cytoplasm to the nucleus. 
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MS-275 induced growth arrest and apoptosis of ATL cells freshly isolated from 
patients. We explored the effect of MS-275 on ATL cells freshly isolated from patients 
with acute-type ATL (Table 2). ATL cells were cultured in the presence of various 
concentrations of MS-275 (0.5-6 μM). After 48 h, MTT activity and the proportion of 
cells positive for annexin V staining were measured; exposure of these cells to MS-275 
induced growth arrest and apoptosis in a dose-dependent manner (Fig 7). On the other 
hand, MS-275 (0.5-6 μM) did not affect the viability of CD4+ T lymphocytes from 
healthy volunteers (n=3, data not shown).   
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Discussion. 
This study shows that the MS-275, SAHA, and LBH589 HDACIs induced 
growth arrest and apoptosis of ATL cells in association with the blockade of signaling 
by NF-κB. Previous study has shown that the blockade of NF-κB by either the 
diterpenoid oridonin [15], the proteasome inhibitor Velcade (Bortezomib) [16], or the 
IκB kinase inhibitor Bay 11-7082 [5] effectively induces apoptosis of ATL cells. Thus, 
NF-κB may be intimately involved in the regulation of pro-survival signals in ATL cells 
and can hence act as an attractive molecular target for treatment of this lethal disease. 
MS-275 was shown to induce apoptosis of B-chronic lymphocytic leukemia 
cells and Jurkat lymphoblastic T-cells via the generation of reactive oxygen species 
(ROS) [17,18]. Since LAQ824, a hydroxamic acid derivative, was found to induce 
apoptosis of leukemia cells in association with the down-regulation of XIAP, which is 
mediated by ROS production [19], and NF-κB negatively regulates ROS production 
[20]. Hence, HDACIs might induce ROS generation via NF-κB inhibition, resulting in 
the induction of apoptosis of leukemia cells. 
We demonstrated the likely mechanism by which HDACIs inhibited NF-κB
signaling in HTLV-1-infected T-cells; MS-275 increased levels of the p65 subunit of 
NF-κB and IκBα in the cytoplasm in conjunction with the down-regulation of NF-κB in 
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the nucleus in the MT-1 cells (Fig 6), suggesting that MS-275 blocked nuclear 
translocation of NF-κB in these cells. Recently, other investigators have shown that 
SAHA inhibited both the cytokine-inducible and constitutive NF-κB activity in 
leukemia or lung cancer cells by blocking degradation of IκBα [21].  
NF-κB is involved in producing proinflammatory cytokines. Targeting this 
transcriptional factor may be an attractive strategy for treating inflammatory diseases.  
For example, we were able to rescue mice from lipopolysaccharide (LPS)-induced 
septic shock by blocking NF-κB signaling by the eight herbal mixture PC-SPES [13]. 
Recent preclinical studies have raised the possibility that HDACIs may be used for 
inflammatory diseases since SAHA decreased the LPS-stimulated production of 
proinflammatory cytokines in murine macrophages [22]. In a murine lupus 
erythematosus model, SAHA decreased production of proinflammatory cytokines such 
as interleukin-6 (IL-6) and -10 and decreased glomerulonephritis [23]. SAHA also 
prevented graft-versus-host disease in a murine bone marrow transplantation model by 
reducing the production of proinflammatory cytokines [24]. Interestingly, SAHA 
preserved the reactivity of donor-lymphocytes against host antigens [24]. We expect that 
HDACIs can block exaggerated cytokine production in lymphocytes and macrophages 
by inhibiting NF-κB. Nevertheless, additional studies are required to clarify all of the 
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molecular mechanisms by which SAHA decreases cytokine production in the 
above-mentioned model systems. 
In summary, HDACIs may be useful in the treatment of patients with ATL by 
targeting NF-κB. Similarly, this group of drugs may be effective against inflammatory 
diseases. Further studies are warranted to evaluate the therapeutic efficacy in this class 
of agents.  
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Figure legends. 
Fig 1. HDACIs inhibited growth of HTLV-1-infected T-cells. 
HTLV-1-infected MT-1, -2, -4, and HUT102 cells were plated in a 96-well plate and 
cultured in the presence of various concentrations of either MS-275 (A), LBH589 (B),
or SAHA (C). Their viability was assed by MTT assay on day 2 of culture. Results 
represent the mean ± SD of 3 experiments performed in triplicate.
Fig 2. Effect of MS-275 on cell cycle distribution of HTLV-1-infected T-cells.  
MT-1, -2, -4, and HUT102 were plated in a 24-well plate and cultured with either 
MS-275 (3 or 6 μM) or diluent control. After 48 h, cell cycle distribution was analyzed 
by flow cytometry by staining with propidium iodide. Results represent the mean ± SD 
of 3 experiments performed in duplicate. Statistical significance was analyzed by paired 
t-test. MS, MS-275. 
Fig 3. MS-275 induced apoptosis of HTLV-1-infected T-cells.  
Cells were plated in a 24-well plate and cultured with either MS-275 (6 μM) or diluent 
control. After 48 h, annexin binding and propidium iodide staining were analyzed by 
FACscan. Lower left quadrants, viable cells. Lower right quadrants, early apoptotic 
cells. Upper right quadrants, nonviable late apoptotic/necrotic cells. These results 
represent one of three experiments performed independently.
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Fig 4. HDACIs modulated levels of cell cycle and apoptosis-regulating proteins in 
HTLV-1-infected T-cells. (Panel A), MT-1, -2, -4, and HUT102 cells were cultured 
with either MS-275 (6 μM) or diluent control. After 48 h, cells were harvested and 
proteins were extracted and subjected to Western blot analyses. The membrane was 
sequentially probed with anti-XIAP, Bcl-2, Bcl-xL, cleaved caspase3, caspase3, p21waf1
and α-tubulin antibodies. Two repeated experiments yielded similar results. (Panel B). 
MT-1 and -4 cells were cultured with either LBH589 (100 or 500 nM) or SAHA (2.5 or 
5 μM). After 48 h, cells were harvested and proteins were extracted and subjected to 
Western blot analyses. The membrane was sequentially probed with anti-XIAP, p21waf1
and α-tubulin antibodies. Two repeated experiments yielded similar results. LBH, 
LBH589.
Fig 5. Effect of HDACIs on NF-κB DNA binding activity in HTLV-1-infected 
T-cells. MT-1, -2, -4, and HUT102 cells were cultured with either MS-275 (6 μM), 
LBH589 (100 nM), or SAHA (5 μM). After 48 h, nuclear proteins were extracted and 
subjected to EMSA. The arrow indicates the gel location of NF-κB bound to DNA. 
Three repeated experiments yielded similar results. WT, wild type and mt, mutant 
oligonucleotides (100 x) were used to compete the cellular lysate NF-κB binding to the 
labeled oligonucleotides.
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Fig 6. MS-275 caused accumulation of NF-κB and IκBα in the cytoplasm (A) and 
down-regulation of levels of NF-κB in the nucleus (B). MT-1, -2, -4, and HUT102 
cells were cultured with MS-275 (3 or 6 μM). After 48 h, cytoplasmic (A) and nuclear 
extracts (B) of these cells were prepared and subjected to Western blot analysis to 
measure the levels of IκBα, the p65 subunit of NF-κB, and α-tubulin as loading control.  
Fig 7. Effect of MS-275 on ATL cells freshly isolated from patients. ATL cells were 
freshly isolated from patients and cultured in the presence of various concentrations of 
MS-275 (0.5-6 μM). After 48 h, MTT activity (A) and the proportion of cells positive 
for annexin V staining (B) were measured.
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Table 1. Inhibit ion of proliferation (ED50) of HTLV-1-infected T-cell lines by 
MS-275, SAHA, and LBH589. 
Concentrations of HDACIs that produced 50% growth inhibition (ED50) of 
HTLV-1-infected T-cells. ED50 was determined by plotting the inhibition of cell 
proliferation (MTT assays) in the presence of increasing concentrations of  
MS-275 (0.1-6 uM, 48 h), SAHA (0.1-5 uM, 48 h), or LB589 (10-1000 nM, 48 h). 
SAHA, suberoylanilide hydroxamic acid; N.R., not reached. 
Table 2. Patient Clinical Characteristics                                     
Patient Age Sex WBC (x10
9
/L) ATL cells (%) Type  Disease Status    
#1 60 F 56,600  73 %  Acute Newly diagnosed 
#2 72 F 47,700  90 %  Acute Newly diagnosed 
  MS-275 SAHA LBH589 
HTLV-1- infected T-cell MT-1 6.0 μM 2.7 μM 100 nM 
 MT-2 6.0 μM 4.6 μM N.R. 
 MT-4 5.4 μM 5.0 μM 58 nM 
 HUT102 N.R. 8.8 μM N.R. 
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